Testing darolutamide triplet therapy for hormone-sensitive prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests if adding darolutamide to standard hormone therapy works better for men whose prostate cancer has spread but still responds to hormones. It aims to see if this 'triplet therapy' helps men live longer with better control of their cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a male age 18 or older and can provide written consent to participate.
- You have metastatic hormone-sensitive prostate cancer (cancer that has spread but still responds to hormone-blocking treatment).
- Your doctor has decided to treat you with a combination of darolutamide plus standard hormone therapy.
- You are physically active enough to take care of yourself (ECOG score of 0 or 1).
- You have not had any other cancer in the past 2 years (except for non-melanoma skin cancer).
- You have no serious heart or blood vessel problems in the last 6 months (like a heart attack, stroke, or uncontrolled heart failure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of using darolutamide (a hormone therapy) together with standard chemotherapy (docetaxel) and hormone therapy (ADT) for men with prostate cancer that has spread. The goal is to see if taking darolutamide on an intermittent schedule works as well as continuous treatment.
This trial tests a combination of two drugs (darolutamide plus hormone therapy) along with a low dose of chemotherapy (docetaxel) for men whose prostate cancer has spread to other parts of the body. It aims to see if this combined approach is safe and effective.
This study tests a combination of three treatments (darolutamide, docetaxel, and hormone therapy) given before surgery for men with locally advanced prostate cancer that hasn't spread. The goal is to see if this approach is safe and effective in shrinking the cancer before surgery.
This study looks at how safe and effective the combination of darolutamide (a tablet), hormone therapy (ADT), and chemotherapy (docetaxel) is for Japanese men with prostate cancer that has spread in a limited way (low volume). It observes people in regular medical care, not in a research setting.
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
This trial tests a combination of two drugs, darolutamide and hormone therapy, for men with prostate cancer that has spread and who are considered frail. The goal is to see if this treatment can improve outcomes for this group of patients.
Hear when a new Metastatic Hormone-sensitive Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.